Skip to contentN
Nutra Pharma Corp
N
NPHCNutra Pharma Corp Q2 2014 · 10-Q
Revenue$98.91K$98.91K+387.1% vs Q2 2013 Net Income-$1.32M-$1.32MN/M vs Q2 2013 EPS Diluted-$0.05-$0.05— vs Q2 2013 Gross Profit$81,949+1,330.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nutra Pharma Corp · CIK 1119643 · Engraved from SEC EDGAR
Operating Cash Flowderived$21,937N/M Margins · derivedGross margin82.9%+54.6 pt vs Q2 2013
Operating margin-647.8%+1117.5 pt vs Q2 2013
Net margin-1333.6%+1666.6 pt vs Q2 2013
ended Jun 30, 2014 · filed Aug 14, 2014 · 45 d after period end